EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes

Yuling Zhang, Hui Cao, Dongran Yu, Wanqi Feng, Shougen Cao, Yanbing Zhou, Ken S Lau, Zequn Li iD

Technology in Cancer Research & Treatment · 2026

DOI: 10.1177/15330338261461720 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Yuling Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Neoplasms, Intracellular Signaling Peptides and Proteins, Drug Resistance, Neoplasm, Carcinogenesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wu Jieping Medical Foundation Clinical Research Special Fund, Young Talent of Lifting Engineering for Science and Technology in Shandong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TIPE3, encoded by the human TNFAIP8L3 gene, is a member of the TNFAIP8 family of lipid second-messenger transfer proteins that connects phosphoinositide signaling with cancer progression, therapeutic resistance, and clinical outcomes. Unlike other TIPE-family members primarily involved in immune regulation or apoptosis, TIPE3 directly transfers phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3) and modulates the PI3K/AKT, MEK/ERK, Wnt/β-catenin, NF-κB, Hedgehog, and mitochondrial stress pathways. Current evidence indicates that TIPE3 generally facilitates tumor growth, invasion, immune remodeling, autophagy, and platinum resistance across various malignancies, including lung, breast, pancreatic, gastric, colorectal, ovarian, cervical cancers, glioblastoma, and acute myeloid leukemia, whereas it may exhibit tumor-suppressive effects in specific contexts, such as head and neck squamous cell carcinoma. This review emphasizes three key concepts: pan-cancer functional duality, localization- and epigenetic-dependent regulation, and TIPE3-guided therapeutic stratification. We also examine conflicting findings, particularly in colorectal cancer, where disparities in mRNA versus protein assessment, tumor composition, immune contexture, subcellular localization, and treatment exposure may contribute to inconsistent prognostic associations. Finally, we propose a translational framework that integrates standardized detection, localization-aware pathology, multi-omics profiling, organoid and patient-derived xenograft validation, AI-assisted inhibitor discovery, RNA-based delivery, and rational combination therapy. Although no TIPE3-targeted therapies have yet reached clinical application, emerging mechanistic and drug discovery studies underscore TIPE3’s potential as a valuable biomarker and therapeutic target in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsIntracellular Signaling Peptides and ProteinsDrug Resistance, NeoplasmCarcinogenesisHumansAnimalsBiomarkers, TumorGene Expression Regulation, NeoplasticSignal TransductionTreatment OutcomeDisease Susceptibility

Stichwörter der Autor:innen

TIPE3precision oncologyprognostic biomarkertargeted therapytumor progression

Substanzen

Intracellular Signaling Peptides and ProteinsTNFAIP8L3 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Qingdao Medical College, Qingdao University, Qingdao, China.
  • Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
  • Center for Computational Systems Biology, Vanderbilt University, Nashville, TN, USA.

ORCID-Profile: Zequn Li

Förderung

  • Wu Jieping Medical Foundation Clinical Research Special Fund
  • Young Talent of Lifting Engineering for Science and Technology in Shandong

Zitieren

APA

Zhang, Y., Cao, H., Yu, D., Feng, W., Cao, S., Zhou, Y., Lau, K. S., & Li, Z. (2026). TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338261461720

Vancouver

Zhang Y, Cao H, Yu D, Feng W, Cao S, Zhou Y, et al. TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338261461720

BibTeX
@article{Zhang2026,
  author = {Zhang, Yuling and Cao, Hui and Yu, Dongran and Feng, Wanqi and Cao, Shougen and Zhou, Yanbing and Lau, Ken S and Li, Zequn},
  title = {TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  doi = {10.1177/15330338261461720}
}
Kostenlos starten →